Skip to main content
Clinical Trials/NCT06049459
NCT06049459
Recruiting
Not Applicable

Novel Amblyopia Treatment With Dichoptic, Disparity-guided, Hand-Eye Coordination Enhanced, Serious, Virtual Reality Games

Marjean Kulp1 site in 1 country8 target enrollmentMarch 14, 2024
ConditionsAmblyopia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Amblyopia
Sponsor
Marjean Kulp
Enrollment
8
Locations
1
Primary Endpoint
Difference in Mean Change in Amblyopic Eye Visual Acuity
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

The goal of this study is to compare the change in amblyopic eye acuity between treatment periods in children with amblyopia, aged 5-17 years. The main question it aims to answer is:

Is a 16-week course of amblyopia treatment using Vivid Vision Therapeutic (Dichoptic) Virtual Reality Games for approx. 25 min/day, 6 days/week more effective for improvement in amblyopic-eye VA, binocularity (stereoacuity, suppression, alignment), contrast sensitivity, attention, oculomotor function, visual-motor integration, and quality of life than 16 weeks of continued glasses alone?

Participants will each serve as their own control and complete:

Treatment period 1: Continued optical correction (glasses) alone for 16 weeks; Treatment period 2: Vivid Vision Therapeutic (Dichoptic) Virtual Reality Games for 16 weeks (approx. 25min/day, 6 days/week) plus continued optical correction

Registry
clinicaltrials.gov
Start Date
March 14, 2024
End Date
December 31, 2026
Last Updated
9 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Marjean Kulp
Responsible Party
Sponsor Investigator
Principal Investigator

Marjean Kulp

Professor

Ohio State University

Eligibility Criteria

Inclusion Criteria

  • Patients ages 5 to 17 years of age
  • Moderate to severe unilateral amblyopia (logMAR best corrected visual acuity 0.3 to 1.3) associated with anisometropia and/or strabismus of ≤5pd
  • Age normal VA in the nonamblyopic eye
  • Spectacle correction (if required) worn for at least 16 weeks, or until stability of VA is demonstrated (\<0.1 logMAR change by the same testing method measured on 2 exams at least 8 weeks apart)
  • Interocular difference of ≥ 3 lines
  • No amblyopia treatment in the past 2 weeks
  • An interpupillary distance of 52-72 mm (inclusive)

Exclusion Criteria

  • Myopia greater than -6.00 diopters (D) spherical equivalent in either eye.
  • Previous intraocular or refractive surgery.
  • Previous dichoptic treatment \> 2 weeks in duration
  • Ocular co-morbidity that may reduce visual acuity determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the participant if the above visual acuity criteria are met).
  • Diplopia more than once per week over the last week prior to enrollment by parental report.
  • Down syndrome or cerebral palsy.
  • Light-induced seizures
  • Known simulator sickness
  • Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Participants with mild speech delay or reading and/or learning disabilities are not excluded.

Outcomes

Primary Outcomes

Difference in Mean Change in Amblyopic Eye Visual Acuity

Time Frame: Baseline to 16 weeks versus 16 weeks to 32 weeks

Optical correction worn for testing using Amblyopia Treatment Study (ATS) protocol; HOTV for ages 5-6 years; E-ETDRS for ages 7 years and older

Secondary Outcomes

  • Difference in Mean Change in Amblyopic-Eye Contrast Sensitivity(Baseline to 16 weeks versus 16 weeks to 32 weeks)
  • Difference in Change in Stereoacuity/Binocularity(Baseline to 16 weeks versus 16 weeks to 32 weeks)
  • Difference in Mean Change in reading eye movements(Baseline to 16 weeks versus 16 weeks to 32 weeks)
  • Difference in Mean Change in Attention(Baseline to 16 weeks versus 16 weeks to 32 weeks)
  • Difference in Mean Change in Pediatric Eye Questionnaire (PedEyeQ)(Baseline to 16 weeks versus 16 weeks to 32 weeks)
  • Difference in Mean Change in visual-motor integration(Baseline to 16 weeks versus 16 weeks to 32 weeks)

Study Sites (1)

Loading locations...

Similar Trials